In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Grace Montgomery

Having built up two years knowledge of the global pharmaceutical industry, Grace reports on a wide range of topics including companies' business strategies, regulatory affairs, market research and product pipelines. Along with story sourcing, she particularly enjoys analyzing industry reports and highlighting companies' corporate business plans, and has attended industry conferences to network and attain exclusive content. Grace enjoys puzzles, baking and keeping active.
Set Alert for Articles By Grace Montgomery

Latest From Grace Montgomery

Alvogen Settles With Celgene Over US Revlimid

Alvogen can sell in the US generic lenalidomide on a volume-limited basis after March 2022, and without volume limitations in early 2026, after settling patent litigation with Celgene relating to the originator’s Revlimid. Dr Reddy's has also settled in Canada.

United States Generic Drugs

Manufacturing Roundup – 1 April 2019

Alvogen’s Lotus subsidiary and Cambrex are expanding their manufacturing capabilities in Taiwan and Canada respectively. As several firms reveal the results of FDA inspections, the agency slaps United Exchange Corporation with a warning letter.

Companies Manufacturing

EMA Informs On Actions To Prevent Brexit-Related Shortages

A Q&A document has been released by the EMA outlining measures EU authorities are taking to prevent medicine shortages as a result of Brexit. Safety, medicine evaluation, clinical trials and supplies are all topics that are addressed in the text.

Brexit Regulation

Shanghai Fosun Details Strategy That Boosted Sales By Over A Third

In 2018, Shanghai Fosun focused on core therapeutic areas, enhanced its international capabilities and promoted industrial upgrading; a strategy that enabled the Chinese firm to post annual sales that rose by over a third to RMB24.9 billion.

Business Strategies Sales & Earnings

Lupin And YL Secure Japanese Nod For Etanercept

Lupin and YL Biologics have obtained approval from Japanese regulator PMDA to manufacture and sell biosimilar etanercept in the region. The firm has also just received GMP certification in the EU for its Indian Pune facility where the drug will be produced.

Japan Approvals

Tadalafil Launches In US Follow Teva's 180-Day Expiry

Multiple generic versions of Eli Lilly’s Cialis (tadalafil) tablets have been launched in the US, following the expiry of Teva’s 180-day exclusivity. The Israeli company introduced its first-to-file version of its Cialis rival in September 2018; now a number of firms have obtained approval, while others have launched generic alternatives.

Approvals Launches
See All